Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.
about
Epigenetic treatment of solid tumours: a review of clinical trialsTrials with 'epigenetic' drugs: an updateNew and emerging HDAC inhibitors for cancer treatmentHistone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium.The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.Antimalarial activity of the anticancer histone deacetylase inhibitor SB939.Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid MalignanciesSubchronic Toxicities of HZ1006, a Hydroxamate-Based Histone Deacetylase Inhibitor, in Beagle Dogs and Sprague-Dawley Rats.Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†.Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.Acetylation- and Methylation-Related Epigenetic Proteins in the Context of Their Targets.Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
P2860
Q26773803-4E0EF5CF-986F-4499-90CE-46D0CE8EF2FFQ27000542-7A4AD8D8-E71E-4E5A-BFD8-E6257BDE20AEQ27022413-48637CF4-3197-4795-B647-E303D7156687Q30251920-61703BEA-9525-493E-A86D-C0515F072874Q33409392-B65596B2-9B04-4501-88CA-8BB458FBB17CQ34640790-90812626-E9BE-4B85-8705-18A06FD0CBD5Q35214924-B73780D1-D24A-4AC3-BC96-1E1067F942E0Q36086326-0009144F-070D-4F2C-A2AC-4062CA096D04Q37226511-D6333015-458C-4822-9D39-27C5999E6947Q37546390-E25F5F5C-D521-47C2-85AA-587A55350AC4Q37993589-BD6BA179-EA20-42E1-9424-1A7CFB3256BAQ38081988-72A12BD1-DA05-49AF-8E58-2AF431B3B8D4Q38336253-FA98DAE8-218F-4F96-8919-BB5795555D71Q39214195-71CD17A9-3A65-4808-ABD8-17AF396F441BQ41553016-E0D035E8-2CF0-4CEE-A3C1-E07A71C29711Q46246730-793F5B33-B3F9-45E2-87B8-75ADFBC2028CQ53842727-E69D1B12-385F-4C49-BC72-3578A3422E3AQ55485574-A741536E-CC24-4460-9757-250BA04B4617
P2860
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase I clinical, pharmacokine ...... s with advanced solid tumours.
@ast
Phase I clinical, pharmacokine ...... s with advanced solid tumours.
@en
Phase I clinical, pharmacokine ...... s with advanced solid tumours.
@nl
type
label
Phase I clinical, pharmacokine ...... s with advanced solid tumours.
@ast
Phase I clinical, pharmacokine ...... s with advanced solid tumours.
@en
Phase I clinical, pharmacokine ...... s with advanced solid tumours.
@nl
prefLabel
Phase I clinical, pharmacokine ...... s with advanced solid tumours.
@ast
Phase I clinical, pharmacokine ...... s with advanced solid tumours.
@en
Phase I clinical, pharmacokine ...... s with advanced solid tumours.
@nl
P2093
P2860
P356
P1476
Phase I clinical, pharmacokine ...... s with advanced solid tumours.
@en
P2093
A Laughlin
A R A Razak
E A Eisenhauer
L-A Stayner
P2860
P2888
P304
P356
10.1038/BJC.2011.13
P407
P577
2011-02-01T00:00:00Z
P5875
P6179
1036295056